Finorify

WAT

Waters Corp. /DE/

$423.92-1.88%

Price

WAT daily closing price
Market cap
$41.64 billion
P/E (TTM)
106
EV/EBITDA
48.99
52W range
$283.32 – $429.72
Volume
1.0M
Sector
Industrials

Waters Corp. /DE/ (WAT) last closed at $423.92, on a daily price path from October 21, 2025 to October 21, 2026. Overview is that price path. Performance is the change in the close over the periods Finorify shows on the stock screen. Financials, cash flow, and margins come from reported quarters. Valuation lists the latest ratios. This snapshot is the Finorify stock screen for WAT, covered for search and blurred for visitors.

Performance

  • 1D+3.31%
  • 5D+4.78%
  • 1M+7.45%
  • 3M+19.63%
  • 6M+36.81%
  • 1Y+33.30%
  • 5Y+33.99%

Financials

WAT revenueQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Over the latest four reported periods ending July 4, 2026, Waters Corp. /DE/ reported revenue of $4.64 billion.

The prior window totaled $3.05 billion, so the latest window is higher than that stretch.

Operating cash flow in the latest window was $549.9 million.

Free cash flow in the latest window was $462.9 million.

These amounts are taken from Waters Corp. /DE/'s SEC filings and are a snapshot as of July 4, 2026. They are not a live price, and they are not a recommendation to buy or sell. Finorify uses the same filings to draw the charts inside the app.

A few ratios from those statements: Profitability: ROE -0.9% (1 of 100). Leverage: D/E 0.33× (87 of 100). Cash generation: FCF margin 10.0% (20 of 100). Net margin: -8.3% (0 of 100). Liquidity: Current 1.86× (93 of 100).

Finorify's notes from those filings, written September 21, 2026: Embedded QA/QC Presence and High Switching Costs. Waters' liquid chromatography and mass spectrometry systems, along with its proprietary Empower chromatography data software, are deeply integrated into highly regulated pharmaceutical quality assurance and quality control (QA/QC) batch-release workflows. Replacing these systems would require substantial capital expense, re-training, and lengthy, costly re-validation with regulatory bodies like the FDA, creating formidable customer retention. Resilient Recurring Revenue from Consumables and Services. The company leverages an extensive global installed base to generate high-margin recurring revenue from specialized consumables (such as proprietary chromatography columns and sample preparation chemistries), software licenses, and long-term service and maintenance contracts, which smooths revenue volatility across broader economic cycles. Technological Leadership and Premium Brand Equity. Waters possesses industry-standard intellectual property and technical leadership in ultra-performance liquid chromatography (UPLC), high-resolution mass spectrometry, and thermal analysis (TA Instruments), enabling the company to command premium pricing and maintain high gross margins. Cyclical Sensitivity to Biopharma R&D and Capital Spending. A substantial portion of Waters' revenue is tied to the life sciences and biopharmaceutical sectors. Reductions in early-stage biotech venture funding, pharmaceutical R&D budget cutbacks, or delays in capital equipment purchases can significantly compress new instrument demand. Geopolitical and China Market Exposure. Waters has significant exposure to international markets, particularly China. Heightened geopolitical friction, trade restrictions, tariffs, or government-led domestic substitution policies in China pose structural risks to revenue growth and international supply chains. Intense Competition from Scaled Analytical Instrument Peers. The company competes directly with large, well-resourced life science and diagnostic conglomerates (such as Thermo Fisher Scientific, Agilent Technologies, and Danaher). Inability to sustain rapid R&D innovation or keep pace with emerging modalities (e.g., cell and gene therapy analytics) could lead to market share erosion.

Cash Flow

WAT free cash flowQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Margins

WAT operating margin

Valuation

P/E (TTM)
106
P/S (TTM)
8.97
EV/EBITDA
48.99

Insights

Advantage

Embedded QA/QC Presence and High Switching Costs

Waters' liquid chromatography and mass spectrometry systems, along with its proprietary Empower chromatography data software, are deeply integrated into highly regulated pharmaceutical quality assurance and quality control (QA/QC) batch-release workflows. Replacing these systems would require substantial capital expense, re-training, and lengthy, costly re-validation with regulatory bodies like the FDA, creating formidable customer retention.

Advantage

Resilient Recurring Revenue from Consumables and Services

The company leverages an extensive global installed base to generate high-margin recurring revenue from specialized consumables (such as proprietary chromatography columns and sample preparation chemistries), software licenses, and long-term service and maintenance contracts, which smooths revenue volatility across broader economic cycles.

Advantage

Technological Leadership and Premium Brand Equity

Waters possesses industry-standard intellectual property and technical leadership in ultra-performance liquid chromatography (UPLC), high-resolution mass spectrometry, and thermal analysis (TA Instruments), enabling the company to command premium pricing and maintain high gross margins.

Risk

Cyclical Sensitivity to Biopharma R&D and Capital Spending

A substantial portion of Waters' revenue is tied to the life sciences and biopharmaceutical sectors. Reductions in early-stage biotech venture funding, pharmaceutical R&D budget cutbacks, or delays in capital equipment purchases can significantly compress new instrument demand.

Risk

Geopolitical and China Market Exposure

Waters has significant exposure to international markets, particularly China. Heightened geopolitical friction, trade restrictions, tariffs, or government-led domestic substitution policies in China pose structural risks to revenue growth and international supply chains.

Risk

Intense Competition from Scaled Analytical Instrument Peers

The company competes directly with large, well-resourced life science and diagnostic conglomerates (such as Thermo Fisher Scientific, Agilent Technologies, and Danaher). Inability to sustain rapid R&D innovation or keep pace with emerging modalities (e.g., cell and gene therapy analytics) could lead to market share erosion.

Read the live analysis in Finorify

Charts, news, and the written notes are in the app. You can open five distinct stocks free. After that, the stock screen is a Finorify Pro feature.

Open WAT in Finorify